epilepsy
Scope
Date
~
-
Bio & Pharma
SK Biopharm targets $311 mn for Cenobamate US sales
South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...
Feb 16, 2024 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm gears up to boost epilepsy drug sales in Europe
SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...
Nov 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharma’s Cenobamate US patent extended by 2032
South Korea's SK Biopharmaceuticals announced on Friday an extension of its US patent for the epilepsy treatment Cenobamate, now set to expire on Oc...
Nov 10, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm to export epilepsy drug tech to Middle Eastern firm
South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...
Aug 18, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals gets OK to sell epilepsy drug in Canada
South Korea's SK Biopharmaceuticals has received approval in Canada to sell its new epilepsy drug Cenobamate under the product name Xcopri. Having e...
Jul 12, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel
South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm holds sales meeting for marketing Cenobamate in US
On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm begins clinical trials of wearable device for detecting epilepsy
SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharma's epilepsy treatment posts impressive growth in US
South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...
Nov 11, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma
South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...
Jul 15, 2022 (Gmt+09:00)
-
Pharamaceuticals
SK Biopharm releases epilepsy treatment in UK
South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...
Dec 21, 2021 (Gmt+09:00)
-
Pharmaceuticals
SK Biopharm aims to make it to global top 10 healthcare firms by 2030
South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...
Jul 02, 2021 (Gmt+09:00)